Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.04.17	FDA Nod For TEVA, Cheers For PRTK, SRNE Hits Goal, SNY Launches Kids Toothpaste (RTTNews)
04.04.17	Sanofi-Pasteur Agrees To Pay $19.9 Mln Fine For Drug Overcharges (RTTNews)
03.04.17	Sanofi Launches First-Ever ACT® Kids Toothpaste in the U.S. (PR Newswire)
03.04.17	Sanofi Launches First-Ever ACT® Kids Toothpaste in the U.S. (PR Newswire)
02.04.17	Switching to Sanofi's Toujeo® Showed Significant Reductions in Blood Sugar and Significantly Lower Incidence of Hypoglycemia in a Real-World Observational Study (PR Newswire)
29.03.17	First Drug For 2 Forms Of MS Gets FDA Nod, RTTR Abuzz, VRTX Gains On Trial Data (RTTNews)
29.03.17	Regeneron Says FDA Okays New Eczema Drug Dupixent (RTTNews)
28.03.17	Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval (PR Newswire)
28.03.17	Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
28.03.17	Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
27.03.17	VIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi - Quick Facts (RTTNews)
21.03.17	Sanofi's Study Says Allergy Sufferer's Sleep To Be Disrupted 4 Times Than Normal (RTTNews)
21.03.17	Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S. (PR Newswire)
14.03.17	Sanofi et Voluntis annoncent une alliance mondiale visant à fournir des solutions numériques de titrage de l'insuline aux personnes atteintes de diabète de type 2 (PR Newswire)
14.03.17	UK Patients Granted Early Access to Sanofi's Innovative Dermatology Treatment Dupilumab by MHRA (PR Newswire)
14.03.17	Sanofi und Voluntis verkünden globale Partnerschaft zur Vermarktung digitaler Insulintitrationslösungen für Patienten mit Typ-2-Diabetes (PR Newswire)
14.03.17	How These Drug Makers Stocks are Faring? -- Sanofi, Impax Laboratories, Heron Therapeutics, and GW Pharma (PR Newswire)
14.03.17	Sanofi and Voluntis Announce a Global Alliance to Deliver Digital Insulin Titration Solutions for People with Type 2 Diabetes (PR Newswire)
14.03.17	Sanofi and Voluntis Announce a Global Alliance to Deliver Digital Insulin Titration Solutions for People with Type 2 Diabetes (PR Newswire)
14.03.17	UK Patients Granted Early Access to Sanofi's Innovative Dermatology Treatment Dupilumab by MHRA (PR Newswire)
13.03.17	OilPrice.com: The Next Big Biotech Breakthrough Could Just be on the Horizon (PR Newswire)
07.03.17	Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions (PR Newswire)
05.03.17	Regeneron, Sanofi: DUPIXENT Study In Atopic Dermatitis Shows Positive Data (RTTNews)
03.03.17	Sanofi Pasteur & AstraZeneca Join To Develop, Commercialize MEDI8897 (RTTNews)
27.02.17	Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses (PR Newswire)
27.02.17	Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses (PR Newswire)
27.02.17	Biotech Stocks Facing FDA Decision In March (RTTNews)
27.02.17	Sanofi, Lonza In Partnership To Build Swiss Biologics Production Facility (RTTNews)
09.02.17	AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban (RTTNews)
09.02.17	Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent (RTTNews)
08.02.17	Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process (PR Newswire)
08.02.17	Sanofi Delivers 2016 Sales and Business EPS Growth at CER (PR Newswire)
08.02.17	Sanofi Stock Up As Q4 Profit More Than Doubles (RTTNews)
08.02.17	Sanofi - Interview du Directeur Général - Résultats 2016 (vidéo) (PR Newswire)
08.02.17	Sanofi CEO Interview - FY 2016 Results (video) (PR Newswire)
08.02.17	Sanofi CEO Interview - FY 2016 Results (video) (PR Newswire)
08.02.17	Sanofi Q4 Profit Up; Sees 2017 Business EPS To Be Stable To -3% At CER (RTTNews)
06.02.17	Research Reports Coverage on Drug Makers Stocks -- Sanofi, Impax Labs, Heron Therapeutics, and Biostar Pharma (PR Newswire)
02.02.17	Sanofi's Xyzal Now Available OTC, GLPG Kicks Off ALBATROSS, PRXL Opens Wallet (RTTNews)
01.02.17	Sanofi Appoints Hugo Fry as General Manager UK (PR Newswire)
01.02.17	Regeneron And Sanofi Say Canada Approves Kevzara (RTTNews)
01.02.17	Regeneron and Sanofi Announce First Approval of Kevzara™ (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada (PR Newswire)
31.01.17	Sanofi Pasteur Announces the Availability of Quadracel™ DTaP-IPV Vaccine for Children 4 Through 6 Years of Age in the U.S. (PR Newswire)
10.01.17	Amgen Issues Statement On Court Decision On Patent Litigation (RTTNews)
09.01.17	Sanofi and ImmuNext Enter into Agreement to Develop Treatments for Autoimmune Diseases (PR Newswire)
06.01.17	OTIC Hits Right Notes, GEMP To Report Data This Month, Busy Year Ahead For RVNC (RTTNews)
06.01.17	Regeneron, Sanofi To Appeal U.S. Court Rulings In Patent Litigation On Praluent (RTTNews)
04.01.17	Sanofi Says Soliqua 100/33 Now Available In U.S. (RTTNews)
03.01.17	Drug Makers Stocks on Investors' Radar -- Immune Pharma, Sanofi, Biostar Pharma, and Heron Therapeutics (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung
26.06.24		Sanofi-Aktie im Minus: Verkauf von Consumer Health steht offenbar in den Startlöchern - möglicher IPO

17.10.24

Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden

04.10.24

Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar

12.09.24

Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach

11.09.24

Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer

02.09.24

Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert

04.07.24

Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht